Haemonetics Corporation
HealthcareNYSE:HAE · New York Stock Exchange
-$1.64 today
Vol 1.05M · Avg 0.84M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $97.3M -42.0% | $167.7M +42.6% | $117.6M +1.9% | $115.4M +166.1% | $43.4M | $498.8M | $487.6M | $476.4M |
| Depreciation & Amortization | $155.7M +34.7% | $115.6M +18.9% | $97.2M +4.2% | $93.3M -4.5% | $97.7M | $1.2B | $374.2M | $1.2B |
| Deferred Income Tax | -$26.5M -407.2% | -$5.2M +52.7% | -$11.0M -330.8% | $4.8M -4.6% | $5.0M | $1.2B | $1.4B | -$1.5B |
| Stock-Based Compensation | $0 -100.0% | $29.6M +4.6% | $28.3M +10.7% | $25.6M +5.0% | $24.4M | $623.4M | $489.0M | $354.6M |
| Change in Working Capital | -$23.7M +76.8% | -$102.0M -36.5% | -$74.7M -392.9% | $25.5M +268.0% | -$15.2M | $484.8M | $350.4M | -$1.6B |
| Accounts Receivables | -$14.9M -313.9% | $7.0M +128.8% | -$24.2M +0.9% | -$24.4M +30.2% | -$35.0M | $1.3B | $592.6M | $1.3B |
| Inventory | $47.4M +173.2% | -$64.7M -7.7% | -$60.1M -295.3% | $30.8M +26.5% | $24.3M | $854.4M | $1.0B | $1.2B |
| Accounts Payables | -$16.6M | $0 -100.0% | $44.6M +12.0% | $39.8M | $0 | $657.0M | $948.2M | -$1.5B |
| Other Working Capital | -$39.6M +10.5% | -$44.2M -26.2% | -$35.0M -69.7% | -$20.6M -357.8% | -$4.5M | $1.3B | $567.4M | $1.3B |
| Other Non-Cash Items | $90.3M +476.4% | -$24.0M -198.4% | $24.4M +187.5% | $8.5M -50.0% | $16.9M | $1.2B | $1.4B | -$1.5B |
| Operating Cash Flow | $293.2M +61.4% | $181.7M -0.0% | $181.8M -33.4% | $273.1M +58.5% | $172.3M | $5.5B | $7.2B | $8.9B |
| Capital Expenditures | -$32.8M +16.5% | -$39.3M +40.8% | -$66.3M +39.8% | -$110.2M -14.2% | -$96.5M | $1.0B | $664.0M | $1.4B |
| Acquisitions (Net) | $1.4M +101.3% | -$107.6M +55.3% | -$240.5M -11927.1% | -$2.0M -124.6% | $8.1M | $769.0M | $937.0M | $1.1B |
| Purchases of Investments | $0 | $0 +100.0% | -$15.6M +53.2% | -$33.2M | $0 | $578.6M | $444.2M | $1.4B |
| Sales of Investments | $0 | $0 | $0 | $0 | $0 | $1.0B | $822.2M | $318.2M |
| Other Investing Activities | -$88.0M -486.3% | -$15.0M | $0 -100.0% | $1.6M -20.5% | $2.0M | $862.8M | $616.4M | $370.0M |
| Investing Cash Flow | -$179.5M -10.9% | -$161.9M +49.8% | -$322.4M -124.2% | -$143.8M -66.5% | -$86.3M | $3.1B | $4.8B | $6.4B |
| Debt Repayment | -$6.3M -101.4% | $447.3M +1084.9% | $37.8M +492.2% | -$9.6M +45.0% | -$17.5M | $602.4M | $680.8M | $759.2M |
| Common Stock Issued | $7.9M | $0 -100.0% | $7.2M | $0 | $0 | $610.8M | $778.8M | $946.8M |
| Common Stock Repurchased | -$175.0M +22.2% | -$225.0M | $0 +100.0% | -$75.0M | $0 | $486.2M | $351.8M | -$1.6B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | -$1.6B | $535.2M | $613.6M |
| Other Financing Activities | -$5.1M +95.5% | -$113.5M -1567.3% | -$6.8M +56.8% | -$15.7M -998.9% | $1.8M | $720.0M | -$1.6B | $1.3B |
| Financing Cash Flow | -$178.5M -264.0% | $108.8M +185.2% | $38.2M +138.0% | -$100.4M -537.3% | -$15.7M | $10.5B | $12.2B | $13.9B |
| Effect of Forex Changes | $3.5M +605.5% | -$685.0K +78.5% | -$3.2M +19.1% | -$3.9M -32.2% | -$3.0M | $1.4B | $1.3B | $1.1B |
| Net Change in Cash | -$61.3M -147.9% | $128.0M +221.1% | -$105.7M -523.2% | $25.0M -62.8% | $67.2M | -$15.5B | $3.2B | $4.9B |
| Free Cash Flow | $260.4M +82.8% | $142.4M +23.4% | $115.5M -29.1% | $162.9M +115.0% | $75.8M | $14.3B | $8.6B | -$16.8B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Catalyst Pharmaceuticals, Inc.
NASDAQ:CPRX
$3.84B
Concentra Group Holdings Parent, Inc.
NYSE:CON
$3.60B
Warby Parker Inc.
NYSE:WRBY
$3.25B
Integer Holdings Corporation
NYSE:ITGR
$3.09B
Beam Therapeutics Inc.
NASDAQ:BEAM
$2.99B
Premier, Inc.
PINC
$2.34B
LeMaitre Vascular, Inc.
NASDAQ:LMAT
$2.10B
DENTSPLY SIRONA Inc.
NASDAQ:XRAY
$2.02B
Bausch Health Companies Inc.
NYSE:BHC
$1.89B
QuidelOrtho Corporation
NASDAQ:QDEL
$963.54M
SEC Filings
Recent regulatory filings
No filings found.
Does HAE generate free cash flow?
Haemonetics Corporation (HAE) generated $260.44M of free cash flow in fiscal 2026.
How much operating cash flow does HAE produce?
Operating cash flow was $293.22M, before capital expenditures of $32.78M.
Explore More
Continue the stock analysis
Jump to another research area for this company.